PR Newswire
07 Feb 2023, 04:00 GMT+10
MELBOURNE, Australia, Feb. 7, 2023 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focusing on developing novel therapeutics for cancers and metabolic diseases, recently announced that the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug application (IND) for its innovative drug HP518, an oral chimeric degrader targeting androgen receptor (AR) for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
HP518 is currently in Phase I clinical trials in Australia. The open-label study approved by FDA will assess the safety, pharmacokinetics, and anti-tumor activity of HP518.
"HP518 is a novel drug expected to address the unmet clinical needs of prostate cancer treatment," said Yuanwei Chen, Ph.D., President and CEO of Hinova. "The available study results of HP518 strengthen our confidence that HP518 is a potentially new treatment for drug resistant prostate cancer. We are making full efforts to advance the clinical study, hoping HP518 will provide more clinical benefits to patients worldwide in the future."
HP518 has been discovered and developed through Hinova's targeted protein degradation drug discovery platform. It has the potential to overcome the drug resistance of prostate cancer that is due to some specific AR mutations. AR is a validated therapeutic target to treat prostate cancer. During the treatment of prostate cancer, drug resistance becomes inevitable due to multiple mechanisms, including AR amplification or mutations, etc. In preclinical studies, HP518 showed excellent selectivity and degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide. HP518 also demonstrated excellent antitumor efficacy in xenograft mouse models.
About Hinova
Hinova is an international and clinical-stage biopharmaceutical company engaged in the development of innovative deuterated and chimeric degraders for cancers and metabolic diseases. The company has established a targeted protein degradation drug discovery platform, which allows Hinova to screen for protein degradation activity rapidly and to accomplish efficient design and optimization of chimeric degraders. Furthermore, Hinova has profound experience in chemical manufacturing control (CMC) of Chimeric degrader compounds. For more information, please visit http://www.hinovapharma.com/en/.
Get a daily dose of Singapore Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Singapore Star.
More InformationWASHINGTON, D.C.: Parts of the U.S. and Canada may not have enough electricity this summer if hot weather causes more people to use...
DOHA, Qatar: President Donald Trump has floated the idea of a new twin-engine warplane, potentially called the F-55, along with a significant...
WASHINGTON, DC - A coalition of 29 U.S. senators, spanning both parties, introduced a resolution on Thursday calling on the Trump administration...
For decades, the US Agency for International Development (USAID) has been vital in combating HIV across the Asia–Pacific region, where...
MIAMI, Florida: Ken Griffin, the CEO of Citadel and a billionaire investor announced this week he would loan his rare first-edition...
GAZA - Israel Air Force pilots have heavily bombarded Gaza this week, killing hundreds and severely wounding hundreds more. The...
WASHINGTON, D.C.: Parts of the U.S. and Canada may not have enough electricity this summer if hot weather causes more people to use...
CORAOPOLIS, Pennsylvania: Dick's Sporting Goods is set to acquire Foot Locker in a US$2.4 billion deal, marking the second major footwear...
BENTONVILLE, Arkansas: Walmart shoppers are bracing for price hikes as the world's largest retailer prepares to pass on the impact...
CHICAGO, Illinois: U.S. cattle farmers have either started rebuilding their herds or are close to it, according to Tyson Foods CEO...
WASHINGTON, D.C.: Smartphone shipments to the United States jumped 30 percent in March as manufacturers including Apple, Samsung, and...
CHICAGO, Illinois: Kraft Heinz is committing US$3 billion to revamp its U.S. manufacturing plants, marking its largest investment in...